RegeneRx Biopharmaceuticals, Inc. · OTC:RGRX

RegeneRx Biopharmaceuticals — Investor Presentation (January 2006)

48 slides from RegeneRx Biopharmaceuticals's investor presentation, Jan 25, 2006

  1. Slide 1: January 2006

    January 2006 Exhibit 99.1

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement The information in this presentation may include certain forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including commercialization

  3. Slide 3: Our Mission

    Our Mission To commercialize our proprietary technology platform, based on Thymosin ßeta (Tß4), to accelerate the healing of acute and chronic wounds caused by disease, injury or other pathology. RegeneRx will explore additional medical markets using strategic partners for product development and ma

  4. Slide 4: Investment Highlights

    Investment Highlights Unique technology platform addresses multiple large and certain niche markets, all with unmet needs – Dermal indications – Ophthalmic indications – Cardiovascular indications Independent researchers have published statistically significant data in major scientific journals show

  5. Slide 5: Recent Key Events

    Recent Key Events Nature publication showing T 4 protects/repairs heart muscle after a Myocardial Infarction (heart attack) in animals (Nov 04) Moved to AMEX and traded under the symbol RGN (Mar 05) Included in Russell Microcap Index (Jul 05) Entered collaboration with Children’ s National Medical C

  6. Slide 6: Management

    Management Dr. Allan Goldstein – Chairman & Chief Scientific Advisor – Founder of RegeneRx, Discoverer of T and Tß4 – Chairman of Biochemistry and Molecular Biology, George Washington Univ School of Medicine – Author of over scientific articles; inventor of more than U.S. Patents J.J. Finkelstein –

  7. Slide 7: Medical Advisory Board

    Medical Advisory Board Allan Goldstein, PhD – Chairman & Chief Scientific Advisor – Professor and Chair, Dept of Biochemistry and Molecular Biology, GWU Med School, Washington, DC Herve Byron, MD, MSc – Ophthalmologist in private practice, editorial board of several medical journals specializing in

  8. Slide 8: Platform Technology

    Platform Technology

  9. Slide 9: RegeneRx Technology Platform

    RegeneRx Technology Platform Thymosin Beta 4 (Tß4) Naturally occurring, conserved molecule found in every cell except red blood cells - highest concentration in blood platelets Key Actin regulator in mammals: – Actin plays central role in cell structure and movement of cells throughout the body – Vi

  10. Slide 10: Response of wound healing (chart slide)

    asuodsey WNWIXEW\ Jo 9 REGENEI

  11. Slide 11: Slide 11

  12. Slide 12: Slide 12

  13. Slide 13: Slide 13

  14. Slide 14: Acute Wound Paradigm

    Acute Wound Paradigm Time (Days, Not to Scale) INFLAMMATION PROLIFERATION REMODELING MATURATION Platelet Aggregation Clot Formation Release of Chemo- attractants Neutrophils/Monocytes – Phagocytose debris – Contaminants Granulation Wound Contraction Re-epithelialization Clot Lysis Collagen Accumulat

  15. Slide 15: Response of wound healing (chart slide)

    asuodsey WNWIXEW) Jo 9% REGENERX

  16. Slide 16: Slide 16

  17. Slide 17: Slide 17

  18. Slide 18: Slide 18

  19. Slide 19: Chronic Wound Paradigm and Tß4

    Chronic Wound Paradigm and T 4 Time (Days, Not to Scale) INFLAMMATION REMODELING MATURATION Down regulation of inflammatory mediators Stimulation of endothelial cells – angiogenesis Stimulation of keratinocytes (epithelial cells) PROLIFERATION Induction of collagen deposition Modulation of actin cyt

  20. Slide 20: Potential Markets for Tß4 Platform

    Potential Markets for T 4 T 4 Platform Ethical/Prescription Drug Pharmacologic Concentrations Ophthalmic Indications Internal Indications Dermal Indications Consumer Products Active Ingredient Channels Corneal Abrasions Dry Eye, Iritis Post Lasik Surgery Viral, Fungal, Bacterial Pathogens Ocular Sur

  21. Slide 21: Clinical Pipeline

    Clinical Pipeline Notes: Phase 2 Phase 1 Preclinical Indications Acute Myocardial Infarction Diabetic Vitrectomy Pressure Ulcer Venous Stasis Ulcer Epidermolysis Bullosa RGN Will Be Sponsoring Five Clinical Trials For Various Indications In 2006 – 72 patient Phase 2 trial initiated – Completion expe

  22. Slide 22: Dermal Indications

    Dermal Indications

  23. Slide 23: Tß4 - Dermal Indications

    T 4 - Dermal Indications Clinical Status Phase 2 trial for Pressure Ulcers – patient trial ongoing – currently enrolling patients – Double-blind, placebo-controlled, dose-escalation study – Primary endpoint: Incidence of healing (complete closure of index wound without drainage); multiple secondary

  24. Slide 24: Tß4 - Dermal Indications

    T 4 - Dermal Indications Courtesy of NIH Re-epithelialization Angiogenesis Collagen Deposition Control Topical T I.P. T Full Thickness Wound Healing and Angiogenesis (Rat Dermal Wounds) Source: Courtesy of National Institutes of Health

  25. Slide 25: Epidermolysis Bullosa (Orphan Drug Status)

    Epidermolysis Bullosa (Orphan Drug Status) Indication overview – Estimated as many as 50,000 Americans have some form of EB – Patients develop blistering from slightest trauma – Affects skin, eyes and internal organs – Caused by genetic abnormalities including inability to effectively produce lamini

  26. Slide 26: Tß4 - Dermal Indications Addressable Market

    T 4 - Dermal Indications Addressable Market Total Addressable Market Opportunity (Annual Sales) Estimated Cost of Therapy per Patient per Year Existing Cases Indication Market Opportunity 1.5 million diabetics suffer from impaired healing problems The incidence of pressure ulcers in the U.S. is 3+ m

  27. Slide 27: Ophthalmic Indication

    Ophthalmic Indication

  28. Slide 28: Tß4 – Ophthalmic Indication

    T 4 – Ophthalmic Indication Clinical Status In pre-clinical studies Tß 4 accelerates healing of corneal epithelial cells, promotes cell adhesion, prevents apoptosis cause by benzalkonium chloride (BAK) Near term pre-IND meeting already scheduled with FDA IND filing expected in H1 2006 Phase 1 trial

  29. Slide 29: Tß4 – Ophthalmic Indications

    T 4 – Ophthalmic Indications Courtesy of NIH Treatment of Corneal Injury & Inflammation Source: Courtesy of Sosne et al., The Kresge Eye Institute/Wayne State University,

  30. Slide 30: Tß4 Promotes Corneal Epithelial Cell Adhesion in vivo

    Mouse cornea heptanol debridement 42 hrs Control T 4 Courtesy of NIH T 4 – Ophthalmic Indications Tß4 Promotes Corneal Epithelial Cell Adhesion in vivo Mouse cornea heptanol debridement 42 hrs Control T Source: Courtesy of National Institutes of Health

  31. Slide 31: Tß4 – Ophthalmic Indications

    T 4 – Ophthalmic Indications Source: Courtesy of Sosne et al., The Kresge Eye Institute/Wayne State University, Slit Lamp Photographs of BALB/c Eyes Following Alkali Injury

  32. Slide 32: Tß4 – Ophthalmic Indications

    T 4 – Ophthalmic Indications Market Opportunity Diabetic Vitrectomy – Surgical removal of the vitreous gel – One of only two effective treatments for Diabetic Retinopathy Laser treatment is the other Total Diabetic Retinopathy market is approximately $500 million Approval for Diabetic Vitrectomy ind

  33. Slide 33: Cardiovascular Indication

    Cardiovascular Indication

  34. Slide 34: Tß4 – Cardiovascular Indication

    T 4 – Cardiovascular Indication Clinical Status In pre-clinical studies, Tß4 showed increased ventricular strength and reduction in heart muscle damage after heart attack Near term pre-IND meeting with FDA IND filing expected H2 2006 Commence Phase 1/2 trial in H2 2006 – 36 patient trial anticipated

  35. Slide 35: Tß4 Improves Cardiovascular Function

    T 4 Improves Cardiovascular Function Source: Courtesy of D. Srivastava et al, University of Texas Southwestern Medical Center and Nature , November 25, 2004 Distribution of Left Ventricular Fractional Shortening or Ejection Fraction After Coronary Ligation Tß4 Significantly Improves Ventricular Func

  36. Slide 36: Tß4 Reduces Cardiovascular Damage

    T 4 Reduces Cardiovascular Damage Source: Courtesy of D. Srivastava et al, University of Texas Southwestern Medical Center and Nature , November 25, 2004. Tß4 Reduces Heart Muscle Damage After Heart Attack p < 0.02

  37. Slide 37: Tß4 Increases Cardiomyocyte Beat Frequency

    T 4 Increases Cardiomyocyte Beat Frequency Source: Courtesy of D. Srivastava et al, University of Texas Southwestern Medical Center and Nature , November 25, 2004. Rare-beating cardiomyocytes migrating from cardiac explants ( in vitro ). Survival = ~14 days Frequent-beating cardiomyocytes migrating

  38. Slide 38: Tß4 Cardiovascular Study Summary

    T 4 Cardiovascular Study Summary Tß4 resulted in a statistically significant reduction in ventricular scarring after acute myocardial infarction (M.I.) when administered within 24 hours post-M.I. (p<0.02) Tß4 also showed statistically significant improvement in ventricular function (p<0.0001) In vit

  39. Slide 39: Tß4 – Cardiovascular Indications

    T 4 – Cardiovascular Indications According to Alan Wasserman, M.D., a noted cardiologist, and Professor and Chairman of the Department of Medicine at The George Washington University School of Medicine: “This paper by Dr. Srivastava and colleagues is one of the most exciting works in the field of ac

  40. Slide 40: Tß4 – Cardiovascular Indications

    T 4 – Cardiovascular Indications Market Opportunity Heart Attack –1 million people annually in U.S. –13+ million suffer from coronary artery disease –Single largest cause of death in U.S. – $250 billion in direct costs per year in U.S. Efficacy for Myocardial Infarction indication potentially opens

  41. Slide 41: Development Strategy

    Development Strategy Out-sourcing business model – PAREXEL International conducting ongoing Phase 2 dermal trials – Assessing CRO’s to conduct upcoming ophthalmic and cardiovascular trials Develop Tß4 through end of Phase clinical trials for dermal, ophthalmic and cardiovascular indications – Initia

  42. Slide 42: Sigma-Tau Relationship

    Sigma-Tau Relationship Licensed certain exclusive European rights to Tß4 to Sigma-Tau in Sigma-Tau will develop Tß4 for internal and external wounds in Europe and certain other contiguous countries – Does not include ophthalmology indications, or OTC and cosmeceutical applications Sigma-Tau is curre

  43. Slide 43: RegeneRx Intellectual Property Portfolio

    RegeneRx Intellectual Property Portfolio Intellectual Property for Tß4 Obtained world-wide rights to recently issued patents under an exclusive license from NIH in 1999 – Broadly cover wound and tissue repair resulting from disease, trauma, and other pathologies for Tß4, fragments, analogues, plus m

  44. Slide 44: Tß4 Manufacturing

    T 4 Manufacturing Manufacturing For Tß4 Tß4, analogues and fragments manufactured by solid-phase peptide synthesis Commercially scalable and cost effective Two manufacturers of bulk peptide identified and qualified Topical formulation completed for Phase 1/2 ophthalmic and cardiovascular clinical tr

  45. Slide 45: 2005 Selected Financial Data

    2005 Selected Financial Data American Stock Exchange symbol: RGN Cash, equivalents and short term investments as of September 30, 2005: $8.9 million Current Burn rate: ~$1.5 million/quarter Shares outstanding: 37.5 million Recent price (1/24/06): $3.35 52-week price range: $1.30 - $4.80 Market capit

  46. Slide 46: Recent and Upcoming Clinical Milestones

    Recent and Upcoming Clinical Milestones Recent and Upcoming Clinical Milestone Targets Q4 2005 H1 2006 H2 2006 Q1 2007 RGN Targets Significant Clinical Milestones Throughout 2006 Initiate Phase 2 Trial for Pressure Ulcers Initiate Phase 2 Trial for Venous Stasis Ulcers Initiate Phase 2 Trial for Epi

  47. Slide 47: Summary

    Summary Tß4 is a conserved, naturally occurring molecule – Excellent safety profile – Active both topically and systemically Statistically significant data published in peer-reviewed journals by independent research institutions showing efficacy in animal models – Dermal, ophthalmic and cardiovascul

  48. Slide 48: REGENERx

    REGENERx

RegeneRx Biopharmaceuticals — Investor Presentation (January 2006) on 6ix